1. Pink Sheet
  2. >>Legal & IP

Patent Judges Could Get Congressional Fix After Federal Circuit Ruling

 
• By Brenda Sandburg

Legal experts testify that best option is for all decisions of the Patent Trial and Appeal Board to be reviewed by PTO director; House IP subcommittee wants to restrict ruling that PTAB judges were not constitutionally appointed.

Capitol Building, Washington DC

An appeals court ruling altering the status of Patent Trial and Appeal Board (PTAB) judges has caused such an uproar among patent owners that the House Judiciary Subcommittee on Courts, Intellectual Property and the Internet called a hearing to ask legal experts what Congress can do to provide a legislative fix.

The four witnesses who testified agreed that the best option would be for Congress to require that all decisions made...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.